Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 14,640 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 14,640 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $85.46, for a total value of $1,251,134.40. Following the completion of the transaction, the chief operating officer directly owned 61,202 shares in the company, valued at approximately $5,230,322.92. The trade was a 19.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR opened at $85.40 on Friday. The stock has a fifty day moving average price of $81.26 and a 200 day moving average price of $71.73. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $103.00. The company has a market cap of $6.97 billion, a PE ratio of -23.21 and a beta of 2.28.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The firm had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The business’s quarterly revenue was down 60.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.88) earnings per share. Analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on KYMR shares. Oppenheimer increased their price target on shares of Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. HC Wainwright boosted their target price on Kymera Therapeutics from $84.00 to $134.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Leerink Partners increased their target price on Kymera Therapeutics from $70.00 to $118.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Jefferies Financial Group initiated coverage on Kymera Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $110.00 price target for the company. Finally, Wall Street Zen downgraded Kymera Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $118.90.

Institutional Trading of Kymera Therapeutics

A number of institutional investors have recently added to or reduced their stakes in KYMR. Baker BROS. Advisors LP lifted its position in shares of Kymera Therapeutics by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after acquiring an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC grew its holdings in shares of Kymera Therapeutics by 17.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after acquiring an additional 1,124,747 shares during the period. Vanguard Group Inc. grew its holdings in shares of Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after acquiring an additional 845,922 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Kymera Therapeutics by 20.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after purchasing an additional 1,061,957 shares in the last quarter. Finally, BVF Inc. IL increased its stake in Kymera Therapeutics by 6.6% in the 2nd quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock valued at $240,138,000 after purchasing an additional 340,909 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.